especially in breeds with a large amount of periocular skin. 4 Developmental or primary entropion is uncommon in cats, with the Persian and Maine Coon breed reported with potential breed predisposition. 5, 6 Secondary entropion may also arise from conformational changes; however, it tends to be due to changes in globe position secondary to senile eyelid laxity with agerelated loss of orbital fat and enophthalmos. Other causes of secondary entropion include changes due to globe size, such as phthisis bulbi. Spastic entropion is induced due to severe blepharospasm and globe retraction in painful ocular conditions such as primary entropion, distichiasis, keratitis (ulcerative and nonulcerative), conjunctivitis, and uveitis. Spastic entropion can exacerbate primary entropion; however, the spastic component may resolve when ocular pain is alleviated (such as healing of a corneal ulcer or application of proparacaine). [1] [2] [3] In cats, the common trends are for spastic entropion due to persistent ocular surface irritation and blepharospasm in young animals and entropion due to secondary entropion related to enophthalmos in older individuals. 5 Cicatricial entropion is uncommon (especially in dogs), and occurs due to acquired lid deformities after to previous surgery, injury, trauma, or chronic inflammation. [1] [2] [3] However, it has also been hypothesized that cicatrices may eventually develop from long-term feline spastic entropion and that this particular form of entropion might more appropriately be called spastic-cicatricial entropion. 3, 4, 7 In both dogs and cats, the lateral lower lid is most commonly involved, frequently also involving the lateral canthus. [1] [2] [3] Longer eyelid length (euryblepharon) has, however, been identified as a risk factor for primary entropion in both dogs and cats. 8 The combination of entropion and ectropion (eversion of the eyelid margin) seen commonly in giant dog breeds with macroblepharon is colloquially referred to as "diamond eye." In brachycephalic dog breeds, such as Chinese Pugs and Shih Tzus, medial entropion may be noted. 1, 2, 9 In a recent study, nearly 71% of Shih Tzus examined had medial entropion, 10 which has been hypothesized to contribute to corneal diseases in these breeds, including pigmentary keratitis. 11, 12 Brachycephalic breeds, such as the Burmese, Himalayan, and Persian, with shallow orbits and prominent globes also have a potential for lagophthalmus and a tendency to develop medial canthal entropion. 13, 14 Primary entropion is more common in dogs than secondary entropion, whereas in cats, secondary entropion is more common than primary. 2 Overall, entropion is more common in canines than in felines, with a prevalence ranging from 6.4 to 7.12 canine cases to 1 feline case reported. 3, 5 Chronic irritation of the cornea and conjunctiva from entropion may lead to the development of corneal edema, ulcerative keratitis, corneal vascularization, and fibrosis, pigmentary keratitis, or even loss of vision with complications becoming more clinically significant over time. 1, 2 Surgical correction has been reported as the only definitive treatment for entropion, and several techniques have been described, such as Hotz-Celsus, lateral canthal closure, fornix-based suture placement, medial canthal Y to V-plasty, stellate rhytidectomy, the Stades method, or some combination of these techniques. [15] [16] [17] [18] A modified, nonsutured Hotz-Celsus using a carbon dioxide (CO 2 ) laser also was recently described in two cats and two dogs. 19 Nonanesthetized injections for entropion have been reported in humans and large animals. In humans, crude substances such as petroleum jelly, paraffin, caoutchouc, or impure silicone were initially used, but often resulted in severe fistula, abscess, and granuloma formation. 20 In large animals, the use of procaine penicillin G and liquid paraffin have been recommended, but are largely discouraged due to similar reactions. 2 Injectable bovine collagen has been used in human cosmetic surgery since the early 1970s. Numerous procedures such as wrinkle reduction, lip augmentation, and lipoatrophy repair have been described in the literature. 21, 22 The safety and efficacy of these products has been well documented; however, early and delayed reactions may still occur. Reported early injection site reactions (up to several days post-treatment) include injection site erythema, edema, pruritus, tenderness, skin discoloration, infection, and hypersensitivity. Delayed injection site reactions (weeks to years post-treatment) include infection, granuloma formation, migration of the product or product clumping, persistent discoloration and hyperpigmentation, and persistent scarring. [22] [23] [24] A newer type of dermal filler, hyaluronic acid (HA), has no organ or species specificity, and therefore in theory, has no risk of an allergic reaction. 20 Thus, HA has become preferred filler in human medicine in the last 15 years. Subdermal fillers have had very limited use in veterinary medicine. In 2002, Wolfer utilized a dose of subdermal bovine collagen into the eyelid margin followed by a modified Stades technique in four cats with eyelid coloboma. All cats in this study remained stable for 12 months post-surgery. 25 All of the subdermal injections were performed by the primary and secondary authors. Each patient was gently restrained with manual restraint for the procedure. Intramuscular (IM) or intravascular (IV) sedatives or general anesthesia were not used in any patient. The patient was prepared for the procedure using dilute 1:50 dilute betadine solution and nonsterile gauze periocularly to remove any visible debris, however, no aseptic technique was utilized. The injection technique and volume of administered material were at the discretion of the investigator performing the injection. Injection techniques used included linear threading ( Figure 1A ), a series of single punctal injections ( Figure 1B) , or a combination of the two. Regardless of the technique, the goal of treatment was a 100% correction of the entropion with no over-correction. Approximately 0.1-0.3 mL of HA filler (Restylane â (dogs) and Restylane Silk â (cats), Galderma Laboratories, L.P., Fort Worth, TX, USA) was injected along the area of entropion just posterior to the dermis of the eyelid skin into the subdermal space using a 27-or 30-gauge needle approximately 1-2 mm ventral to the eyelid margin ( Figure 2 ). Post-operative medications were initiated or continued on a case-by-case, clinician-dependent basis. A protective collar was not placed on any patient. The owners were instructed to return in 1-week, 1-month, 3-months, 6-months, and 12-months for re-evaluation post-procedure. Serial photographs were taken at all time points. All patients that did not resolve with intradermal injection were treated with permanent, corrective eyelid surgery. Corrective surgery was performed based on clinician-preference but included Hotz-Celsus with or without lateral wedge resection in all cases. Affected eyelids from select corrective surgery cases were submitted for histopathology to the Comparative Ocular Pathology Laboratory of Wisconsin (COPLOW).
| Data analysis
Data were analyzed a two-sample equal variance 2-tailed Student's t-test (Microsoft Excel   TM , Redmond, WA, USA). Data are reported as median and mean values AE standard deviation (SD). Probability values of ≤.05 were considered significant.
| RESULTS
Forty animals (28 dogs [5 male intact (MI); 8 male castrated (MC); 6 female intact (FI); 9 female spayed (FS)]; 12 cats [6 MC; 6 FS]) were included in the study (Table 1) . Median age for the dogs was 3.1 years (mean:
F I G U R E 1 Injection techniques for subdermal hyaluronic acid filler. A, Linear threading technique: A 27-or 30-gauge needle is inserted through the skin ("X") and tunneled (white dotted line) through the subdermal space past the area of entropion. Upon exiting, hyaluronic acid filler is injected (blue bleb) continuously (white solid arrow) to fill the subdermal space to evert the eyelid and resolve the entropion. B, Single puncture technique: A 27-or 30-gauge needle is inserted through the skin ("X") and the subdermal filler is injected multifocally to resolve the entropion (blue bleb) 5.1 AE 5.0 years, range: 0.33-18 years) while median age for the cats was significantly higher at 9.7 years (mean 10.6 AE 5.5 years, range: 1.1-19.6 years, P = .005). The most common dog breed included in the study was the English bulldog (n = 5, 17.9%), Labrador retriever (n = 3, 10.7%), Bernese mountain dog (n = 2, 7.1%) German Shepherd dog (n = 2, 7.1%), Chow Chow (n = 2, 7.1%), and one each (n = 1, 3.6%) of the following other breeds: Great Dane, English Springer Spaniel, Golden retriever, Rottweiler, Chihuahua, Saint Bernard, Chinese Shar-Pei, Mastiff, Clumber Spaniel, Cocker Spaniel, Doberman, Bichon Frise, Siberian Husky, Wheaten Terrier. Domestic shorthair (DSH) was the most common feline breed (n = 8, 66.7%), followed Persian (n = 2, 16.7%) and one each (n = 1, 8.3%) of the following: Siamese and Himalayan. For dogs, the most common site of entropion was the lower eyelid of both eyes (OU) (n = 9, 32.1%), followed by the lower eyelid of the left eye (OS) (n = 6, 21.4%), the upper eyelid of the right eye (OD) (n = 4, 14.3%), lower eyelid OD (n = 3, 10.7%), upper and lower eyelids OS (n = 2, 7.1%), upper eyelid OS (n = 2, 7.1%), and one case (n = 1, 3.6%) each of the following: upper and lower OU, upper OU. For cats, lower eyelid entropion OU was most common (n = 8, 66.7%), followed by two cases (n = 2, 16.7%) of the following each: lower OD and lower OS. No cases of upper eyelid entropion were observed in felines.
The etiopathogenesis for canine entropion cases was most commonly diagnosed as primary (n = 17, 60.7%) in dogs, followed by senile secondary (n = 7, 25%), spastic (n = 2, 7.14%) and cicatricial (n = 2, 7.1%). For cats, senile secondary entropion was most commonly diagnosed (n = 8, 66.7%), followed by primary (n = 3, 25%) and cicatricial (n = 1, 8.3%). All cases of secondary entropion were characterized as age-related (senile) entropion. Severity ranged from mild to severe in all species, with mild being the most common in dogs (n = 12, 42.9%) and cats (n = 7, 58.3%), followed by moderate (n = 11 (39.3%) and n = 4 (33.3%), respectively) and lastly, severe (n = 5 (17.9%) and n = 1 (8.3%), respectively). All three dogs with spastic entropion (n = 3) were diagnosed with a superficial corneal ulceration, indicative by positive fluorescein uptake, on presentation.
The median follow-up time for all cases was 152.5 days (mean: 194.6 AE 142.7 days; range 9-419 days). For dogs, the median follow-up time was 121.5 days (mean 173.5 AE 144.1 days; range 9-419 days). For cats, the median follow-up time was 259 days (mean 240.1 AE 128.0 days; range 14-365 days). The median follow-up time between species was not statistically significant. The average number of recheck appointments for dogs throughout the study was 4.0 AE 1.4 visits, versus cats were 4.3 AE 1.6 visits.
Most cases were clinically improving in blepharospasm, epiphora and all corneal ulcerations were healed (if present) by the first recheck for dogs and cats (average 9.1 AE 4.28 days and 7.3 AE 0.78 days, respectively). Most cases requiring repeat injections were present at the first re-evaluation in both dogs and cats (n = 9 (32.1%) and n = 1 (8.3%), respectively). Repeat injections were not required at all in most patients (n = 18 (69.2%) in dogs; n = 9 (75%) in cats). The remainder dog (n = 1) required a repeat injection of dermal filler at 113 days post-operatively, and the remaining cats (n = 2) received a repeat injection at days 21 and 31. One cat required a third injection at day 120. Representative cases of a two canine and feline are shown in Figures 3A-F, 4A -F and 5A-F, respectively.
Three dog cases (average age 11.9 AE 5.2 years) and two feline cases (mean age 17.7 AE 1.9 year) died or were euthanized during the study for unrelated causes. One dog was euthanized due to severe protein-losing enteropathy, and the other two cases were unknown, however, not related to the eyes. The two feline cases died due to progressive, severe renal disease. Three dogs failed, necessitating permanent corrective surgery at 121 days, 154 days, and 419 days post-procedure (mean = 231.3 AE 133.38 days). All three dogs were young at presentation (median 0.5 years, mean 0.54 AE 0.19 years) and were characterized by severe entropion. One cat failed 14 days post-procedure necessitating permanent corrective eyelid surgery and was also characterized as severe entropion. One cat developed progressive malacia and globe rupture of the left eye due to unknown cause 224 days post-procedure necessitating enucleation and subsequently is included as a failure. The patient was doing well with no signs of entropion prior to presentation. Two canine cases were lost to follow-up (20 and 98 days postprocedure at last examination). No feline cases were lost to follow-up. Histopathology and immunohistochemistry for HA were performed on the eyelids of two cases (one dog (case 7) and one cat (case 32)) requiring permanent corrective surgery. Histopathology of both cases showed the superficial and deep dermis and conjunctival substantia propria were multifocally expanded by multiple cavitated lesions containing dense basophilic amorphous material (consistent with the subdermal filler) surrounded by a thin layer of fusiform to plump elongated cells ( Figure 6 ). There was mild neutrophilic and histiocytic infiltration surrounding the lakes of subdermal amorphous material. Immunohistochemistry with Alcian blue/Periodic acid-Schiff (PAS) stain revealed the material to be intensely Alcian blue positive, consistent with a glycosaminoglycan (hyaluronic acid) (Figure 7A-D) . Immunohistochemistry stain for CD204 revealed that some of the elongated fusiform cells surrounding the lakes of amorphous material were CD204 positive, and thus were consistent with macrophages ( Figure 8 ). Chemistry. This high molecular weight polysaccharide was found initially in vitreous of bovine eyes, forming its name, from "hyaloid" and "uronic acid." 26 HA belongs to a class of glycosoaminoglycans (GAGs) and is the earliest evolutional form. GAGs are the major structural component of the extracellular matrix of the eye, dermis, connective tissue, synovial fluid, and other tissues including the ground substance of the fascia, hyaline cartilage, synovial joint fluid among others in the body. These GAGs act to bind a significant amount of water, which assists in hydration and providing skin turgor. HA also acts as a connective agent by forming the matrix fluid by which collagen and elastin fibers are intermixed. 27, 28 Unlike bovine collagen, as previously used by Wolfer, 25 the chemical structure of HA is highly conserved across species, with no antigenic specificity for species or tissue, and thereby having a low potential for hypersensitivity reactions. Further, different sources of HA, either from bacterial and animal sources, will produce identically structured polymers. 27, 28 The half-life of HA as a single entity into human tissues is very brief, with degradation occurring within only a few days. This is due to naturally occurring hyaluronidases that will degrade and digest noncrosslinked HA. 22, 27, 28 In order to extend its durability and longevity, HA is chemically modified by crosslinking hyaluronan polymer chains to yield a single molecule. Restylane â , an FDA-approved human dermal filler available for human use since 2005, is composed of similarly sized HA particles derived from bacterial fermentation, with a concentration of 100 000 HA particles per milliliter (mL). The medium-density gel is supplied as a 20 mg/mL suspension (2%) in 1.0 mL of physiologic saline solution (pH-7.0) and packaged as a disposable 1.0 mL syringe with a sterile, 30-gauge needle. 29 Restylane Silk â , a newer low-density FDA-approved bacterial fermentation filler since 2015, is composed of 500 000 HA particles per mL, or is 1/5th the size of a regular Restylane â HA particle. Subsequently, the length of time before bio-resorption time is different among the two products. Restylane â has been reported to last approximately 6-12 months, however, one study with improvement up to 18 months after 1 injection has been reported. 30, 31 Restylane Silk â is shorter-acting, due to the smaller HA particle size, and is reported for use up to 6-months in humans. 29 The use of these products was chosen specifically for these species due to their specific characteristics. Canines in this case series tended to have more cases of moderate and severe entropion versus felines, although this may be skewed due to the smaller number of feline cases. The larger particle size of Restylane â was hypothesized to last longer than the smaller particle of Restylane Silk â . Overall, there was a low long-term recurrence rate of entropion and need for a second treatment. Most repeat injections for both canines and felines (n = 10, 25%) occurred at the first recheck visit 1-week post-injection. Only one dog required repeat injection 113 days (case 5) post-operatively, while 2 cats needed second injections at days 21 (case 34) and 31 (case 31), with the third injection in one cat at day 120 (case 31). The shorter time frame for repeat injection in felines may be indicative of the shorter longevity of the Restylane Silk â , however clinically, all cats that received a second (or third) injection did well with no evidence of immunologic reaction. Additionally, Restylane Silk â was utilized in felines for its shorter duration of action to minimize the potential risk of sarcoma formation, although this side effect of subdermal fillers has not been reported in the veterinary literature to the authors' knowledge. Several authors have reported chronic inflammation as suspected pathogenesis for many feline neoplasms, including feline injection site sarcomas following long-acting antibiotics, anti-inflammatories, chemotherapy agents, nonabsorbable suture material, and microchip implants. [32] [33] [34] [35] [36] [37] Wolfer previously reported that the subdermal injection of the collagen in the shoulder area of these cats failed to elicit a positive skin reaction. 25 Routine light microscopic examination of tissue biopsy from As with most retrospective cases, follow-up duration was recommended at the time of the subdermal injection, and only two canine cases (5%) were lost to follow-up. Communication with the owners of these two cases was attempted but unsuccessful. It is also notable that five cases in the study (n = 5; 12.5%) died or were euthanized during the course of the study due to unrelated causes. This gives rise to the circumstance that the subdermal injection can be used especially in older to geriatric animals that may be immunocompromised or at a higher risk for general anesthesia or sedation. The procedure did not require sedation in any case, which is a major benefit in geriatric patients. If unsuccessful, then surgery may become necessary. Three of five dogs (60%) presenting with "severe" entropion (>4 mm of inward rolling of eyelid) required permanent corrective surgery in this case series. These three were young dogs (cases 7, 8, 22) at presentation (median 0.5 years, mean 0.54 AE 0.19 years) and all had primary entropion, characterized by macropalpebral fissure. One "failed" dog (case 8) had permanent corrective surgery 419 days after subdermal injection, allowing for the craniofacial structures to develop before pursuing permanent surgery. The two remaining "severe" entropion cases (cases 21, 26) were older (mean 13.0 AE 2.0 years) with secondary, senile entropion that occurred due to muscle atrophy and retro-orbital fat loss. In the feline cases, the only one severe entropion case (Case 39; 8.3%) also required permanent corrective surgery. In this specific case, the authors discussed this potential with the owners prior to subdermal injection, however, the owners wanted to give the injection an opportunity to work prior to pursuing surgery. The follow-up time for this case was short, only 14 days, as it was evident at that time that the injection would not be adequate to resolve the entropion. The last feline case (case 32) that presented 224 days post-injection with globe rupture. The owner had reported that the cat was slightly more blepharospastic prior to presentation, however, the cause of the acute globe rupture was not definitively determined. This case required a third subdermal injection at day 120 post-injection, due to severe lower entropion OS secondary to third eyelid CO 2 laser excision secondary to severe lipogranulomatous conjunctivitis approximately 6 months prior to initial injection. Based on the results of this small case series, care should be taken with patients with severe entropion, especially young dogs with primary entropion, with the use of a subdermal HA injection, as many will not respond sufficiently. In cases 4, 7-9, and 22, the subdermal filler was used as a temporary repair (in lieu of periocular tacking or surgical staple procedures) to allow the dogs immediate comfort in spastic entropion or in cases of primary entropion, to grow before permanent surgery was performed. A benefit to HA subdermal fillers is that the injection can be reversed if complications such as over-correction (ectropion), excessive dermal filler, or granuloma formation. In general, there are two main ways to remove HA filler: extraction or dissolution. 26 Excision can be performed by creating a pinprick in the area of HA filler and squeezing out excessive subdermal filler. This method can be unpredictable, and not recommended if granuloma formation is present due to continued inflammation. The second method is dissolution using an injection of hyaluronidase. In human medicine, two types of hyaluronidase injectable suspensions are available (Hylenex â (human recombinant) and Vitrase â (ovine)). Hyaluronidase not only hydrolyses HA, but also cleaves chondroitin sulfate from proteoglycans resulting in enzymatic degradation of HA. 26 In humans, this injection can be performed immediately after injection of HA if undesirable locations are injected, up to months or years later if necessary. 38 This injection, while not necessary in this study, could be considered for future studies if concern for local injection site reactions or complications is noted post-operatively after HA injection. A new, 2.4% veterinary HA product, has recently been released for the use of eyelid augmentation (Alyna, Anvision, Salt Lake City, UT, USA), that is, a similar product to Restylane â and Restylane Silk â . 39 The expense of this veterinary product is much less than its human counterpart, and therefore likely more accessible to clinicians. Since the termination of this case series, the authors have used this veterinary product with similar success. Further studies regarding this veterinary HA dermal filler are warranted.
| DISCUSSION
The subdermal injection technique of HA filler is a simple, effective, long-acting, minimally time-consuming procedure that allows for immediate relief of mild to moderate entropion in both cats and dogs without sedation or anesthesia. This technique is particularly advantageous for geriatric patients or patients at higher anesthetic risk.
